Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

The purpose of this research study is to test the efficacy of ADT on prostate-specific membrane antigen (PSMA), a marker of prostate cancer, before and after scheduled ADT. Follow up will be 48 months your prostate removal to do a blood test and log if any new or worsening symptoms have occurred as a part of your standard-of-care (SOC).

Trial Details

NCT ID

NCT07455903

Phase

PHASE2

Sponsor

Baptist Health South Florida

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Leuprolide
Degarelix
Relugolix
Triptorelin
Bicalutamide
18-F Flotufolastat PSMA PET

Locations (sample)

Miami, Florida, United States|25.77427,-80.19366

Key Eligibility Criteria

Signed informed consent must be obtained prior to participation in the study.
Males aged ≥18 years.
ECOG performance status ≤ 1
Histologically confirmed adenocarcinoma of the prostate in a patient amenable to radical prostatectomy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →